Epstein-Barr virus infection and risk of lymphoma: immunoblot analysis of antibody responses against EBV-related proteins in a large series of lymphoma subjects and matched controls
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
17557295
DOI
10.1002/ijc.22857
Knihovny.cz E-resources
- MeSH
- Leukemia, Lymphocytic, Chronic, B-Cell epidemiology virology MeSH
- Adult MeSH
- Enzyme-Linked Immunosorbent Assay MeSH
- Immunoblotting * MeSH
- Immunoglobulin G blood MeSH
- Incidence MeSH
- Epstein-Barr Virus Infections complications epidemiology immunology MeSH
- Middle Aged MeSH
- Humans MeSH
- Lymphoma epidemiology immunology virology MeSH
- Odds Ratio MeSH
- Antibodies, Viral blood MeSH
- Risk Factors MeSH
- Aged MeSH
- Case-Control Studies MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic epidemiology MeSH
- France epidemiology MeSH
- Ireland epidemiology MeSH
- Italy epidemiology MeSH
- Germany epidemiology MeSH
- Spain epidemiology MeSH
- Names of Substances
- Immunoglobulin G MeSH
- Antibodies, Viral MeSH
Epstein-Barr Virus (EBV) is consistently associated with distinct lymphoproliferative malignancies and aberrant EBV antibody patterns are found in most EBV cancer patients. We evaluate the detection of an abnormal reactive serological pattern to EBV (ab_EBV) infection and the risk of lymphoma in a multicentric case-control study. Serum samples were collected at study entry from 1,085 incident lymphoma cases from Spain, France, Germany, Czech Republic, Italy and 1,153 age, sex and country matched controls. EBV immunoglobulin G (IgG) serostatus was evaluated through a peptide-based ELISA combining immunodominant epitopes of EBNA1 (BKRF1) and VCA-p18 (BFRF3). Further, immunoblot analysis was performed to evaluate distinct antibody diversity patterns to EBV early antigens (EA), besides EBNA1, VCA-p18, VCA-p40 (BdRF1) and Zebra (BZLF1). Patients with chronic active EBV infection and aberrant EBV activity were characterized as having an abnormal reactive pattern (ab_EBV). Ab_EBV was observed in 20.9% of 2,238 included subjects with an increased proportion of cases presenting ab_EBV as compared to the control population (23.9% vs. 18.0% p = 0.001). Ab_EBV positivity was a risk factor for all lymphomas combined (odds ratio [OR] = 1.42, 95% confidence interval [CI]=1.15-1.74), and specifically for chronic lymphocytic leukaemia (OR = 2.96, 95%CI = 2.22-3.95). Lower levels of ab_EBV were observed for follicular lymphoma (OR = 0.38, 95%CI = 0.15-0.98). EBV may be involved in a larger subset of lymphomas among clinically immunocompetent subjects than previously thought, probably explained by an underlying loss of immune control of EBV latent infection. Ab_EBV is a useful tool to explore EBV imbalances preceding or paralleling possible EBV associated oncogenic events.
References provided by Crossref.org
Ubiquitin Modification of the Epstein-Barr Virus Immediate Early Transactivator Zta
